Buradasınız

Anasayfa » Content

Hipertansif ve Normotensif Kronik Üremik Hastalarda Lipid Profili

Lipid profiles in hypertensive and normotensive chronic uremic patients

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 1997

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
To elicit whether lipid profile of hypertensive chronic uremic patients was different from those of normotensive patients, this study was performed in 14 hypertensive and 27 normotensive chronic uremic patients. Eighteen patients (9 hypertensive and 9 normotensive) were ongoing regular hemodialysis. Also 12 healthy volunteers was included to the study as control. Basal insulin levels and serum lipid profiles were determined in venous blood samples taken from the patients after 14-hour fasting. There were no any differences between hypertensive and normotensive patients in respect to mean age and body mass index. Serum triglyceride, total-cholesterol, LDL, VLDL, Apo-B, lipoprotein-(a) and insulin levels of the hypertensive patients were significantly higher than those of the normotensive ones. In dialyzed and non-dialyzed uremic patients, lipid abnormalities were not different. As a result, it was found that hypertensive chronic uremic patients had greater lipid abnormalities than normotensive patients. Therefore, it may considered that atherosclerosis will occur earlier in hypertensive chronic uremic patients. [Journal of Turgut Özal Medical Center 1997;4(3):274-278]
Bookmark/Search this post with
Abstract (Original Language): 
Bu çalışma hipertansif ve normotensif kronik üremik hastalar arasında lipid profili yönünden farklılık bulunup bulunmadığını araştırmak amacıyla 14'ü hipertansif 27'si normotensif toplam 41 kronik ürem il i hasta üzerinde yapıldı. Bu hastaların 18'i (9 normotensif 9 hipertansif kronik hemodiyaliz programında idi. Kontrol grubu olarak ise sağlıklı 12 kişi alındı. Gece boyunca 14 saatlik açlık sonrası alınan venöz kan örneklerinde bazal insülin düzeyi ve serum lipid profili tayini yapıldı. Hipertansif ve normotensif hastalar arasında yaş ortalaması ve vücut kitle indeksi yönünden önemli bir farklılık yoktu. Hipertansif grupta serum trigliserid, total kolesterol, LDL, VLDL, Apo-B, Lipoprotein-(a) ve insülin düzeyleri normotensif gruba göre önemli derecede daha yüksek, HDL düzeyleri ise daha düşük bulundu. Hemodiyalize giren ve girmeyen hastalar arasında da lipid profili yönünden farklılık yoktu. Sonuç olarak, hipertansif kronik üremik hastalarda lipid anormalliklerinin normotensiflerden daha fazla olduğu tespit edildi. Bu nedenle hipertansif üremik hastalarda aterosklerozun daha erken ve ciddi boyutlarda ortaya çıkacağı sonucuna varıldı. [Turgut Özal Tıp Merkezi Dergisi 1997;4(3):274-278]
FULL TEXT (PDF): 
PDF icon arastirmax-hipertansif-normotensif-kronik-uremik-hastalarda-lipid-profili.pdf
  • 3
274-278
  • Turkish

REFERENCES

References: 

1. Grutzmacher
P
, Marz W, Peshke B, Gross W, Schoeppe L. Lipoproteins and apolipoproteins during the progression of chronic renal disease. Nephron 1988; 50:103.
2. Roullet JB, Lacour B, Yvert JP, Prat JJ, Drueke J. Factors of increase in serum triglyceride rich lipoproteins in uremic rats.
Kidney Int 1988; 27:420-5.
3. Chan MK. Lipid metabolism in renal failure. Clin Biochem
1990; 23:61-5.
4. Roullet JB, Lacour B, Yvert JP, Drueke J. Correction by insulin of disturbed triglyceride-rich lipoprotein metabolism in rats with chronic renal failure. Am J Physiol 1986; 250: E 373¬6.
5.
parathyroid hormone adversely affects lipid metabolism in chronic renal failure. Kidney Int 1990; 37: 854-8.
6. Chan MK, Varghese Z, Persaud JM, Baillod RA, Moorhead
JF. Hyperlipidemia in patients on maintenance hemo and peritoneal dialysis : the relative pathogenetic roles of triglyceride production and triglyceride removal. Clin
Nephrol. 1982; 17:183.
7. Marigliano A, Tedde R, Sechi LA, et al. Insulinemia and blood pressure: Relationship in patients with primary and secondary hypertension and with or without glucose metabolism impairment. Am. J Hyperten. 1990; 3: 521-6.
8. World Health Organization: Arterial hypertension Report of a WHO Expert Committee. WHO Technical Report Series.
1978:628.
9. Russel RM. Nutritional Assesment. In: Wyngaarden JB, Smith LH, Bennett JC.(eds.), Cecil Texbook of Medicine (19th ed.),
WB Saunders, Philadelphia 1991:1151-8.
10. Levely AS, Madaio MP, Perrone RD. Laboratory assement of renal disease: Clearance, urinalysis and renal biopsy. In: Brenner-Rector(ed.), The Kidney, WB Saunders, Philadelphia
1991:929.
11. Fridewald WT, Levely RI, Frederickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative centrifuge. Clin. Chem. 1972; 18: 499-502.
Journal of Turgut Özal Medical Center 4(3):1997
277
Kronik üremik hastalarda lipid profili
HZ. Tombul ve ark.
12. Parsy D, Dracon M, Cachera C, Parra HJ, Vanhoutte G, Tacquet A, Fruchart JC. Lipoprotein abnormalities in chronic hemodialysis patients. Nephrol Dial Transplant 1988; 3: 51-6.
13. Senti M, Romero R, Pedro-Botet J, Pelegri A, Nogues X,
Rubies-Prat J. Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal
failure. Kidney Int. 1992; 41:1394-99.
14. Grundy SM. Management of hyperlipidemia of kidney
disease. Kidney Int 1990; 37: 847-53.
15. Chan MK, Varghese Z, Moorhead JF. Lipid abnormalities in uremia, dialysis and transplantation. Kidney Int 1981; 19:
625-37.
16. Massry SG, Akmal M. Lipid abnormalities, renal failure and
parathyroid hormone. Am J Med 1989; 87: 5-42.
17.
V, Salvadori M. Lipids and apolipoproteins change during the progression of chronic renal failure. Clin Nephrol 1992; 38(5):
264-70.
18. Mak RHK, De Fronzo RA. Glucose and insulin metabolism in
uremia. Nephron 1992; 61: 377-82.
19.
hipertansiyon. Yeni Tıp Dergisi 1996; 13(1): 33-4.
20. Harter HR, Meltzer VN, Tindira CA, Naumovich AD,
Goldberg AP. Comparison of the effects of prazosin versus propranonol on plasma lipoprotein lipids in patients receiving
hemodialysis. Am J Med 1986; 80(2A): 82-9.
21. Riegel W, Horl WH, Heidland A. Long-term effects of
nifedipine on carbohydrate and lipid metabolism in hypertansive hemodialyzed patients. Clin Wochenschr 1986; 64(21): 1124-30.
22. Meltzer VN, Goldberg AP, Tindira CA, Naumovich AD,
Harter HR. Effects of prazosin and propranonol on blood pressure and plasma lipids in patients undergoing chronic
hemodialysis. Am J Cardiol 1984; 53(3): 40-5.
23. Joven J, Viella E, Ahmad S, Cheung MC, Brunzell JD.
Lipoprotein heterogeneity in end-stage renal disease.Kidney
Int 1993; 43: 410-8.
24. Ohta J, Matsuda I. Apolipoprotein and lipid abnormalities in uremic children on hemodialysis. Clin Chim Acta 1985;
147:145-54.
25. Ron D, Oven I, Aviram M, Better OS, Brook JG.
Accumulation of lipoprotein remnants in patients with chronic renal failure. Atherosclerosis 1983; 46: 67-75.
26. Joven J, Rubies-Prat J, Espinel E, Chacon P, Olmos A, Masdeu S. Apoprotein A-1 and high density lipoprotein subfraction in patients with chronic renal failure receiving hemodialysis. Nephron 1985; 40: 451-4.
27. Parra HJ, Mejdour H, Cachera C, Dracon M, Tacquet A, Fruchart JC: Lipoprotein-a in patients with chronic renal failure treated by hemodialysis. Clin Chem 1987; 33: 721.
28. Okura Y, Saku K, Hirata K, Zhang B, Liu R, Ogahara S,
Naito S, Kajiyama G, Arakawa K. Serum lipoprotein-a levels in maintenance hemodialysis patients. Nephron 1993; 65: 46¬50.
29. Cressman MD, Heyka RJ, Pganini EP, O'Neil J, Skibinski CI,
Hoff HF. Lipoprotein-a is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation
1992; 86: 475-82.
30. Yavuz M,
Güllül
ü M, Ersoy A, Dilek K, Yurtkuran M. Hemodiyaliz hastalarında serum lipoprotein (a) düzeyi. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi 1995; 4(1): 37-9.
31.
Kompanse kronik böbrek yetmezlikli hastalarda serum lipoprotein (a) düzeyi. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi 1996; 5(1): 11-5.
32. Lacour B, Drueke TB, Lipid metabolism In: Massry SG, Glassock RJ (eds) Texbook of Nephrology, Williams- Wilkins, Baltimore-USA 1989:1228-38.
33. Attman PO, Alaupovic P: Lipid and apolipoprotein profiles of uremic dyslipoproteinemia-relation to renal function and dialysis. Nephron 1991; 57: 401-10.

Thank you for copying data from http://www.arastirmax.com